美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ALMS近 30 天 17 則 · 第 1 / 1 頁
- Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
- Alumis to Participate in Upcoming September Investor Conferences
- Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
- Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
- Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
- Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints
- Sector Update: Healthcare Stocks Advance Late Afternoon
- Sector Update: Healthcare Stocks Advance Wednesday Afternoon
- Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says
- ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
- Tesla, Apple, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today’s Market
- Top Midday Gainers
- A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It
- Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
- Alumis Phase 2b lupus trial misses primary and secondary endpoints
- Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
- Alumis’ TYK2 drug fails in key lupus study
- Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
- Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
- Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
- Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。